Displaying drugs 14776 - 14800 of 14987 in total
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
VSF-173
VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive...
Investigational
Matched Description: … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression …
Dipipanone
Experimental
Illicit
2,3,4,5,6-Pentafluorobenzyl Alcohol
Experimental
Iodobenzene
Experimental
ES-936
Experimental
S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
Experimental
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
Experimental
4-Fluorophenethyl Alcohol
Experimental
1,3,5-trichlorobenzene
Experimental
N-(Chlorophenyl)-N'-hydroxyguanidine
Experimental
(R)-4-Nitrostyrene oxide
Experimental
1-[4-(hydroxymethyl)phenyl]guanidine
Experimental
1-(4-thiophen-2-ylphenyl)methanamine
Experimental
4-(2-aminoethyl)-2-ethylphenol
Experimental
(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE
Experimental
Displaying drugs 14776 - 14800 of 14987 in total